01 1Cipla
01 1EDARAVONE
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2021-11-16
Pay. Date : 2021-09-28
DMF Number : 36244
Submission : 2021-09-24
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is EDARAVONE, with a corresponding US DMF Number 36244.
Remarkably, this DMF maintains an Active status since its submission on September 24, 2021, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 16, 2021, and payment made on September 28, 2021, indicating their dedication to facilitating drug approvals, Categorized as Type II
